<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/article/pii/S0140673616313228</prism:url><dc:identifier>doi:10.1016/S0140-6736(16)31322-8</dc:identifier><eid>1-s2.0-S0140673616313228</eid><prism:doi>10.1016/S0140-6736(16)31322-8</prism:doi><pii>S0140-6736(16)31322-8</pii><dc:title>Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial </dc:title><prism:publicationName>The Lancet</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><prism:issn>01406736</prism:issn><prism:coverDate>2016-11-04</prism:coverDate><prism:coverDisplayDate>29 October–4 November 2016</prism:coverDisplayDate><openaccess>0</openaccess><openaccessArticle>false</openaccessArticle><openaccessType/><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType/><openaccessUserLicense/><link href="http://api.elsevier.com/content/article/pii/S0140673616313228" rel="self"/><link href="http://www.sciencedirect.com/science/article/pii/S0140673616313228" rel="scidir"/></coredata></full-text-retrieval-response>